Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation

内皮环氧合酶、肾脏损伤和血压调节

基本信息

  • 批准号:
    10763638
  • 负责人:
  • 金额:
    $ 32.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

Epidemiological and outcomes studies in patients, as well as studies in rodent models, reveal that renal ischemic kidney injury and unilateral obstructive uropathy brings on long-term consequences: hypertension and chronic kidney disease. Major pathophysiological contributors include impaired renal hemodynamics, endothelial dilator dysfunction, and endothelial cell inflammation. Because the renal microcirculation lacks efficient regenerative capacity, acute damage to the microcirculation can lead to long-term changes in renal hemodynamics that predispose patients to hypertension and chronic kidney disease. A class of arachidonic acid metabolites, epoxyeicosatrienoic acids (EETs) increase renal blood flow and improve endothelial cell function. Not known is the contribution of CYP2C epoxygenases, soluble epoxide hydrolase (sEH), and regioisomeric EETs to salt-sensitive hypertension and chronic kidney disease following obstructive uropathy and renal ischemic injury. We hypothesize that decreased endothelial EET levels result in endothelial dysfunction and impaired renal hemodynamics following renal ischemic injury or urinary tract obstruction. The immediate goals of this project are to determine the ability for endothelial EETs to improve endothelial- dependent afferent arteriolar dilation, to decrease endothelial inflammation, and to prevent salt-sensitive hypertension and chronic kidney disease following unilateral ureter obstruction (UUO) or ischemia/reperfusion (I/R) kidney injury. This project will utilize pharmacological as well as global and tissue-specific genetic manipulation of CYP2C, sEH, and EETs. We will obtain our immediate goals by completing three aims. Aim 1 will test the hypothesis that decreased EET levels or EET function contributes to the development of salt- sensitive hypertension and chronic kidney disease following UUO or I/R kidney injury. Aim 2 will test the hypothesis that increasing endothelial EET levels will improve renal microvascular endothelial function following UUO or I/R kidney injury to prevent salt-sensitive hypertension and chronic kidney disease. Aim 3 will test the hypothesis that pharmacological approaches to increase EET levels can prevent the long-term salt-sensitive hypertensive and chronic kidney injury following UUO or I/R kidney injury. Accordingly, our findings promise to advance the field forward by not only enhancing our understanding of the pathophysiological mechanisms whereby UUO or I/R kidney injury leads to chronic kidney disease but also leading to new therapeutic treatments.
患者的流行病学和结局研究,以及啮齿动物模型的研究表明,肾缺血

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John D Imig其他文献

John D Imig的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John D Imig', 18)}}的其他基金

Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
内皮环氧合酶、肾脏损伤和血压调节
  • 批准号:
    10625377
  • 财政年份:
    2021
  • 资助金额:
    $ 32.97万
  • 项目类别:
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
内皮环氧合酶、肾脏损伤和血压调节
  • 批准号:
    10415003
  • 财政年份:
    2021
  • 资助金额:
    $ 32.97万
  • 项目类别:
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
内皮环氧合酶、肾脏损伤和血压调节
  • 批准号:
    10317475
  • 财政年份:
    2021
  • 资助金额:
    $ 32.97万
  • 项目类别:
Eicosanoid-based Therapy for Diabetes
基于类二十烷酸的糖尿病疗法
  • 批准号:
    9129716
  • 财政年份:
    2015
  • 资助金额:
    $ 32.97万
  • 项目类别:
Eicosanoid-based Therapy for Diabetes
基于类二十烷酸的糖尿病疗法
  • 批准号:
    8962739
  • 财政年份:
    2015
  • 资助金额:
    $ 32.97万
  • 项目类别:
P450 Monooxygenases and Renal Vascular Function
P450 单加氧酶和肾血管功能
  • 批准号:
    7758889
  • 财政年份:
    2009
  • 资助金额:
    $ 32.97万
  • 项目类别:
Renal Endothelial Dysfunction in Salt-Sensitive Hypertension
盐敏感性高血压中的肾内皮功能障碍
  • 批准号:
    7433776
  • 财政年份:
    2007
  • 资助金额:
    $ 32.97万
  • 项目类别:
Eicosanoids and Renal Microvascular Function
类二十烷酸与肾微血管功能
  • 批准号:
    7459643
  • 财政年份:
    2007
  • 资助金额:
    $ 32.97万
  • 项目类别:
Renal Endothelial Dysfunction in Na-Sensitive Hypertensi
钠敏感性高血压的肾内皮功能障碍
  • 批准号:
    7228244
  • 财政年份:
    2006
  • 资助金额:
    $ 32.97万
  • 项目类别:
Novel epoxide hydrolase inhibitor for stroke prevention
用于预防中风的新型环氧化物水解酶抑制剂
  • 批准号:
    6990653
  • 财政年份:
    2005
  • 资助金额:
    $ 32.97万
  • 项目类别:

相似海外基金

Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
内皮环氧合酶、肾脏损伤和血压调节
  • 批准号:
    10415003
  • 财政年份:
    2021
  • 资助金额:
    $ 32.97万
  • 项目类别:
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
内皮环氧合酶、肾脏损伤和血压调节
  • 批准号:
    10625377
  • 财政年份:
    2021
  • 资助金额:
    $ 32.97万
  • 项目类别:
Endothelial Epoxygenase, Kidney Injury, and Blood Pressure Regulation
内皮环氧合酶、肾脏损伤和血压调节
  • 批准号:
    10317475
  • 财政年份:
    2021
  • 资助金额:
    $ 32.97万
  • 项目类别:
RENAL CYTOCHROME P450 EPOXYGENASE IN DIABETIC METABOLIC SYNDROME
糖尿病代谢综合征中的肾细胞色素 P450 环氧合酶
  • 批准号:
    8357157
  • 财政年份:
    2011
  • 资助金额:
    $ 32.97万
  • 项目类别:
P450 Epoxygenase Mechanisms of Opioid Analgesia
P450 环氧合酶阿片类药物镇痛机制
  • 批准号:
    8434943
  • 财政年份:
    2010
  • 资助金额:
    $ 32.97万
  • 项目类别:
Role of IGF-1R in breast cancer proliferation and survival via CYP1A1 epoxygenase
IGF-1R 通过 CYP1A1 环氧化酶在乳腺癌增殖和生存中的作用
  • 批准号:
    7802543
  • 财政年份:
    2010
  • 资助金额:
    $ 32.97万
  • 项目类别:
Role of IGF-1R in breast cancer proliferation and survival via CYP1A1 epoxygenase
IGF-1R 通过 CYP1A1 环氧化酶在乳腺癌增殖和生存中的作用
  • 批准号:
    8260379
  • 财政年份:
    2010
  • 资助金额:
    $ 32.97万
  • 项目类别:
P450 Epoxygenase Mechanisms of Opioid Analgesia
P450 环氧合酶阿片类药物镇痛机制
  • 批准号:
    8234084
  • 财政年份:
    2010
  • 资助金额:
    $ 32.97万
  • 项目类别:
RENAL CYTOCHROME P450 EPOXYGENASE IN DIABETIC METABOLIC SYNDROME
糖尿病代谢综合征中的肾细胞色素 P450 环氧合酶
  • 批准号:
    8166169
  • 财政年份:
    2010
  • 资助金额:
    $ 32.97万
  • 项目类别:
Role of IGF-1R in breast cancer proliferation and survival via CYP1A1 epoxygenase
IGF-1R 通过 CYP1A1 环氧化酶在乳腺癌增殖和生存中的作用
  • 批准号:
    8054780
  • 财政年份:
    2010
  • 资助金额:
    $ 32.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了